The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis

PharmacoEconomics
Paul TappendenKeith Brownlee

Abstract

Cystic fibrosis (CF) affects over 9,000 people in the UK and limits life expectancy. CF patients are susceptible to lung infections, most commonly Pseudomonas aeruginosa. Once infection is established, patients require lifetime treatment using nebulised antibiotics. Newer dry powder formulations of antibiotics may reduce treatment burden and improve compliance. Our objective was to evaluate the cost effectiveness of (i) colistimethate sodium dry powder for inhalation (DPI) and (ii) tobramycin DPI versus nebulised tobramycin for the treatment of chronic P. aeruginosa lung infection in patients with CF from the perspective of the National Health Service (NHS) and Personal Social Services (PSS). We developed a state transition model based on transitions between three strata of lung function measured in terms of forced expiratory volume in 1 second (FEV1) % predicted. Additional health states representing post-lung transplantation and dead are also modelled. The model structure was informed by systematic reviews of evidence concerning the plausibility of potential relationships between intermediate endpoints and final outcomes. The model assumes that treatment impacts on FEV1 trajectory, which manifest as changes in health-related ...Continue Reading

References

Feb 14, 2003·The Journal of Pediatrics·Michael S YiJoel Tsevat
Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Richard IlesSarah Vowler
Sep 13, 2005·Health and Quality of Life Outcomes·Elisabeth StåhlBo Lundbäck
Oct 26, 2005·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·J ThorntonA K Webb
Feb 24, 2006·Health Economics·Mark J SculpherChris McCabe
Dec 22, 2006·The European Respiratory Journal·J A DodgeJ Wilsher
Dec 15, 2007·BMJ : British Medical Journal·Jane C DaviesAndrew Bush
Nov 16, 2010·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Michael W KonstanDavid E Geller
Jun 28, 2013·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Sofia DiasA E Ades

❮ Previous
Next ❯

Citations

Sep 16, 2014·Current Opinion in Pulmonary Medicine·Lesley Uttley, Paul Tappenden
Nov 7, 2014·Expert Opinion on Drug Delivery·Anne H de Boer, Paul Hagedoorn
Jun 9, 2015·Annals of the American Thoracic Society·Michael S SchechterCori L Daines
Dec 16, 2016·Drug Development and Industrial Pharmacy·Stefano GiovagnoliMaurizio Ricci
Sep 2, 2018·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Laura S GoldLarry Kessler
May 25, 2021·Seminars in Respiratory and Critical Care Medicine·Alicia B Mitchell, Allan R Glanville
Feb 11, 2019·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Bishal MohindruJennifer A Whitty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2021 Meta ULC. All rights reserved